Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

Provided herein are compositions and methods for treating pulmonary hypertension. In particular, provided herein are dry powder formulations of fasudil for delivery to the lung.

Ketogenic compositions include a non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the R-enantiomer. The compositions are enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer to provide alternative benefits. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 50.5% to 99.5% by enantiomeric equivalents of R-beta-hydroxybutyrate and from about 49.5% to about 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate.

Bee venom nanoparticles and methods of synthesizing bee venom nanoparticles are provided. The bee venom nanoparticles may be synthesized by drying bee venom, suspending the dried bee venom in a solvent to form a first bee venom solution, spraying the first bee venom solution into boiling water under ultrasonic conditions to form a bee venom solution including the bee venom nanoparticles, stirring the bee venom solution including the bee venom nanoparticles, and freeze-drying the bee venom solution. The resulting nanoparticles may be used in pharmaceutical compositions, and may be useful for their antimicrobial activities.

Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

Described herein are methods to size particles of 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as compositions comprising 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone particles having defined particle size distributions. Also described are methods of use of the resulting particles.

The present invention primarily relates to the use of Homoeriodictyol (HED) or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof for reducing the gastric acid secretion-stimulating effect of N-Acetyl-4-aminophenol (Paracetamol).

A single dose vaporizable formulation including room temperature solid extracts and other botanical extracts and methods of processing and packaging single dose portions of vaporizable formulations. Also, methods of dispensing single dose portions, including segmented dose formulations and applicator-tab devices for vaporizers. A vaporizer having a heating chamber element with an indentation or cavity sized to receive a similarly-shaped, single dose vaporizable formulation.

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.